港股医药再调整，港股通医疗ETF（159137）、港股通创新药ETF（520880）跌2%！低吸时机到了？场内持续溢价！

Core Viewpoint - The Hong Kong stock market is experiencing a broad adjustment, with the Hang Seng Index down nearly 1%, particularly affecting the healthcare sector, which is seeing declines in major pharmaceutical stocks and ETFs [1][10]. Group 1: Market Performance - The Hong Kong healthcare sector opened lower and continued to decline, with the Hong Kong Stock Connect Medical ETF (Huabao, 159137) dropping by 2%, and major stocks like WuXi Biologics falling over 5% [1][10]. - The Hong Kong Stock Connect Innovative Drug ETF (520880), which exclusively tracks innovative drugs, fell by over 2%, with leading stocks such as BeiGene and CanSino Biologics also declining by more than 2% [3][10]. - The trading volume for the Hong Kong Stock Connect Innovative Drug ETF exceeded 200 million yuan, indicating strong buying interest despite the price drop [12]. Group 2: Regulatory and Market Insights - The National Medical Products Administration of China announced that 76 innovative drugs are expected to be approved by 2025, positioning China as a global leader in this area, with the total transaction value for overseas licensing of innovative drugs expected to exceed 130 billion USD [14]. - Analysts believe that the Chinese innovative drug sector is entering a phase of simultaneous benefits from "going global, technology, and policy," leading to a revaluation of innovative drug stocks [15]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds passively track the Hang Seng Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and effectively manages risks associated with less liquid stocks [5][6][16]. - The top ten stocks in the ETF account for over 73% of its weight, highlighting the dominance of leading companies in the innovative drug sector [17].